# Novel Drug Approvals at FDA

## Novel Drug Approvals for 2023

8. **Ryzneuta**: Approved on November 16, 2023, Ryzneuta, with the active ingredient efbemalenograstim alfa-vuxw, is used for treating neutropenia.

9. **Orserdu**: Orserdu, containing elacestrant, was approved on January 27, 2023, for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

10. **Elrexfio**: Approved on August 14, 2023, Elrexfio, which contains elranatamab-bcmm, is used for treating adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.

11. **Epkinly**: On May 19, 2023, Epkinly, with the active ingredient epcoritamab-bysp, was approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy.

12. **Wainua**: Approved on December 21, 2023, Wainua, containing eplontersen, is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis.

13. **Velsipity**: Velsipity, with the active ingredient etrasimod, was approved on October 12, 2023, for the treatment of moderately to severely active ulcerative colitis in adults.

14. **Veozah**: Approved on May 12, 2023, Veozah, containing fezolinetant, is used for the treatment of moderate to severe hot flashes caused by menopause.
